Roche (ADR)

Roche reports that Giredestrant in combination with Ibrance failed to meet the primary endpoint of a statistically significant improvement in progression-free survival in patients with advanced breast cancer. This was the first of two late-stage studies in the first-line setting; results from the second study are expected next year. Chief Medical Officer Levi Garraway still sees opportunities for Giredestrant in combination with other drugs, for example in the adjuvant setting. » More on finanzen.net

JPMorgan confirms its rating for Roche at "Neutral" with a target of 350 francs. Analyst Richard Vosser notes that Phase II data from partner Zealand Pharma for the weight-loss drug Petrelintide showed somewhat smaller weight reductions, but a Phase III study could still see mid-double-digit reductions if more responsive female participants are included. Vosser therefore expects only a small share-price decline for Roche. » More on finanzen.net

Roche reports positive phase II results for the obesity drug petrelintide: participants lost on average up to 10.7% of their weight after 28 weeks versus 1.7% with placebo. The drug showed a favorable tolerability profile and a discontinuation rate due to adverse events of 4.8% in the highest-dose arm, comparable to placebo. Roche plans to present final data at a medical congress and proceed to phase III trials; topline results from the second phase II study (obesity with type 2 diabetes) are expected in H2 2026, and a combination study is set to start in 2026. » More on de.investing.com

Roche reports that the phase II investigational drug Petrelintide (study Zupreme‑1) produced a mean weight loss of up to 10.7% after 28 weeks versus 1.7% in the placebo group. The drug showed a favorable tolerability profile and a discontinuation rate for adverse events of 4.8% in the highest‑dose arm, practically identical to placebo. Final study data are to be presented at a medical congress; Roche plans phase III designs, expects topline results from the Zupreme‑2 study (obesity with type 2 diabetes) in H2 2026, and intends to start a combination study with CT‑388 in 2026. » More on finanzen.net

Roche reports that fenebrutinib met its primary endpoint in a late‑stage study, reducing the annualized relapse rate by 51 percent over at least 96 weeks compared with Aubagio. The results are consistent with earlier studies that showed a 59 percent reduction in relapsing MS. Secondary endpoints showed significant reductions in brain lesions, and a separate study in primary progressive MS also met its primary endpoint. » More on finanzen.net